NCT06781112: A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 35 | RoW | albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and tislelizumab ( 200mg)., radical concurrent chemoradiotherapy combined with tislelizumab (200mg) treatment | Weiwei Zhang | TPF, Immunotherapy, Nasopharyngeal Carcinoma, Phase II Clinical Study | 12/27 | 12/28 | | |
